U.S. markets open in 4 hours 7 minutes
  • S&P Futures

    3,930.25
    +26.50 (+0.68%)
     
  • Dow Futures

    31,637.00
    +216.00 (+0.69%)
     
  • Nasdaq Futures

    12,123.75
    +83.25 (+0.69%)
     
  • Russell 2000 Futures

    1,786.70
    +16.90 (+0.95%)
     
  • Crude Oil

    111.07
    +1.50 (+1.37%)
     
  • Gold

    1,828.00
    +3.20 (+0.18%)
     
  • Silver

    21.32
    +0.15 (+0.69%)
     
  • EUR/USD

    1.0590
    +0.0003 (+0.03%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    27.00
    -0.23 (-0.84%)
     
  • GBP/USD

    1.2274
    +0.0004 (+0.03%)
     
  • USD/JPY

    135.7580
    +0.3120 (+0.23%)
     
  • BTC-USD

    21,148.39
    -298.74 (-1.39%)
     
  • CMC Crypto 200

    461.72
    -0.08 (-0.02%)
     
  • FTSE 100

    7,337.61
    +79.29 (+1.09%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

'Pharma Bro' Martin Shkreli has launched a newsletter to talk investing, science, and tech a month after his release from prison

·2 min read
Martin Shkreli
In this Feb. 4, 2016 file photo, Pharmaceutical chief Martin Shkreli smiles on Capitol Hill in Washington.AP Photo/Susan Walsh
  • Former pharmaceutical executive Martin Shkreli launched a tech and investing newsletter Thursday.

  • The first entry of "Martin's Newsletter" was subtitled "This post was written in prison."

  • Shkreli is currently residing in a halfway house after his early release from federal prison.

Martin Shkreli has a Substack.

The former pharmaceutical exec and "Pharma Bro" launched his tech and investing newsletter on Thursday, just over a month after he was released from prison having served less than five years of his seven-year sentence.

Shkreli is now living in a halfway house pending his planned release in September.

The first entry of Martin's Newsletter, subtitled "This post was written in prison," is a rambling collection of book reviews, predictions, and musings, including whether he would be un-banned from Twitter.

By 2025, for example, he projects "TSLA nears $10T market cap, Musk becomes the first trillionaire."

The newsletter arrived amid a pitched proxy battle between Shkreli and a group of activist investors seeking to take control of his pharmaceutical firm Turing.

A lawyer for Shkreli declined to comment when contacted by Insider.

Shkreli was found guilty of securities fraud in 2017 and faced a separate antitrust lawsuit for raising the price of the rare, life-saving anti-parasitic drug Daraprim by 5,000%.

Earlier this year, a federal judge barred him from the pharmaceutical industry for life and ordered him to pay a $64.6 million fine.

As for the newsletter, Shkreli said that it wouldn't be free and, in a nod to his infamous raising of Daraprim, said: "Expect a 5000% price increase soon. Just don't mix up relative and absolute changes. That's been a matter of confusion in the past."

Brent Hodge, who directed the "Pharma Bro" documentary, told the New York Post that Shkreli "likes to play up his position as a supervillain."

Read the original article on Business Insider